Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Antitumor activity of a small-molecule inhibitor of the histone kinase Haspin.

Huertas D, Soler M, Moreto J, Villanueva A, Martinez A, Vidal A, Charlton M, Moffat D, Patel S, McDermott J, Owen J, Brotherton D, Krige D, Cuthill S, Esteller M.

Oncogene. 2012 Mar 15;31(11):1408-18. doi: 10.1038/onc.2011.335. Epub 2011 Aug 1.

2.

Haspin inhibitors reveal centromeric functions of Aurora B in chromosome segregation.

Wang F, Ulyanova NP, Daum JR, Patnaik D, Kateneva AV, Gorbsky GJ, Higgins JM.

J Cell Biol. 2012 Oct 15;199(2):251-68. doi: 10.1083/jcb.201205106.

3.

Growth suppression and mitotic defect induced by JNJ-7706621, an inhibitor of cyclin-dependent kinases and aurora kinases.

Matsuhashi A, Ohno T, Kimura M, Hara A, Saio M, Nagano A, Kawai G, Saitou M, Takigami I, Yamada K, Okano Y, Shimizu K.

Curr Cancer Drug Targets. 2012 Jul;12(6):625-39.

PMID:
22463590
4.

TAK-960, a novel, orally available, selective inhibitor of polo-like kinase 1, shows broad-spectrum preclinical antitumor activity in multiple dosing regimens.

Hikichi Y, Honda K, Hikami K, Miyashita H, Kaieda I, Murai S, Uchiyama N, Hasegawa M, Kawamoto T, Sato T, Ichikawa T, Cao S, Nie Z, Zhang L, Yang J, Kuida K, Kupperman E.

Mol Cancer Ther. 2012 Mar;11(3):700-9. doi: 10.1158/1535-7163.MCT-11-0762. Epub 2011 Dec 21.

5.

Modulation of the chromatin phosphoproteome by the Haspin protein kinase.

Maiolica A, de Medina-Redondo M, Schoof EM, Chaikuad A, Villa F, Gatti M, Jeganathan S, Lou HJ, Novy K, Hauri S, Toprak UH, Herzog F, Meraldi P, Penengo L, Turk BE, Knapp S, Linding R, Aebersold R.

Mol Cell Proteomics. 2014 Jul;13(7):1724-40. doi: 10.1074/mcp.M113.034819. Epub 2014 Apr 14.

6.

MK-5108, a highly selective Aurora-A kinase inhibitor, shows antitumor activity alone and in combination with docetaxel.

Shimomura T, Hasako S, Nakatsuru Y, Mita T, Ichikawa K, Kodera T, Sakai T, Nambu T, Miyamoto M, Takahashi I, Miki S, Kawanishi N, Ohkubo M, Kotani H, Iwasawa Y.

Mol Cancer Ther. 2010 Jan;9(1):157-66. doi: 10.1158/1535-7163.MCT-09-0609. Epub 2010 Jan 6.

7.

Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines.

Payton M, Bush TL, Chung G, Ziegler B, Eden P, McElroy P, Ross S, Cee VJ, Deak HL, Hodous BL, Nguyen HN, Olivieri PR, Romero K, Schenkel LB, Bak A, Stanton M, Dussault I, Patel VF, Geuns-Meyer S, Radinsky R, Kendall RL.

Cancer Res. 2010 Dec 1;70(23):9846-54. doi: 10.1158/0008-5472.CAN-10-3001. Epub 2010 Oct 8.

8.

The kinase haspin is required for mitotic histone H3 Thr 3 phosphorylation and normal metaphase chromosome alignment.

Dai J, Sultan S, Taylor SS, Higgins JM.

Genes Dev. 2005 Feb 15;19(4):472-88. Epub 2005 Jan 28.

9.

Phosphorylation of threonine 3 on histone H3 by haspin kinase is required for meiosis I in mouse oocytes.

Nguyen AL, Gentilello AS, Balboula AZ, Shrivastava V, Ohring J, Schindler K.

J Cell Sci. 2014 Dec 1;127(Pt 23):5066-78. doi: 10.1242/jcs.158840. Epub 2014 Oct 14.

10.

Haspin: a newly discovered regulator of mitotic chromosome behavior.

Higgins JM.

Chromosoma. 2010 Apr;119(2):137-47. doi: 10.1007/s00412-009-0250-4. Epub 2009 Dec 8. Review.

11.

Polo-like kinase-1 triggers histone phosphorylation by Haspin in mitosis.

Zhou L, Tian X, Zhu C, Wang F, Higgins JM.

EMBO Rep. 2014 Mar;15(3):273-81. doi: 10.1002/embr.201338080. Epub 2014 Jan 10.

12.

Haspin: a mitotic histone kinase required for metaphase chromosome alignment.

Dai J, Higgins JM.

Cell Cycle. 2005 May;4(5):665-8. Epub 2005 May 4.

PMID:
15846065
13.

Identification of small molecule inhibitors of the mitotic kinase haspin by high-throughput screening using a homogeneous time-resolved fluorescence resonance energy transfer assay.

Patnaik D, Jun Xian, Glicksman MA, Cuny GD, Stein RL, Higgins JM.

J Biomol Screen. 2008 Dec;13(10):1025-34. doi: 10.1177/1087057108326081. Epub 2008 Oct 31.

14.

Identification and characterization of plant Haspin kinase as a histone H3 threonine kinase.

Kurihara D, Matsunaga S, Omura T, Higashiyama T, Fukui K.

BMC Plant Biol. 2011 Apr 28;11:73. doi: 10.1186/1471-2229-11-73.

15.

Autoinhibition and Polo-dependent multisite phosphorylation restrict activity of the histone H3 kinase Haspin to mitosis.

Ghenoiu C, Wheelock MS, Funabiki H.

Mol Cell. 2013 Dec 12;52(5):734-45. doi: 10.1016/j.molcel.2013.10.002. Epub 2013 Oct 31.

16.

Aurora kinase inhibitors: a new class of drugs targeting the regulatory mitotic system.

Pérez Fidalgo JA, Roda D, Roselló S, Rodríguez-Braun E, Cervantes A.

Clin Transl Oncol. 2009 Dec;11(12):787-98. Review.

PMID:
20045785
17.

Yeast haspin kinase regulates polarity cues necessary for mitotic spindle positioning and is required to tolerate mitotic arrest.

Panigada D, Grianti P, Nespoli A, Rotondo G, Castro DG, Quadri R, Piatti S, Plevani P, Muzi-Falconi M.

Dev Cell. 2013 Sep 16;26(5):483-95. doi: 10.1016/j.devcel.2013.07.013. Epub 2013 Aug 22.

18.

Tasisulam sodium, an antitumor agent that inhibits mitotic progression and induces vascular normalization.

Meier T, Uhlik M, Chintharlapalli S, Dowless M, Van Horn R, Stewart J, Blosser W, Cook J, Young D, Ye X, Evans G, Credille K, Ballard D, Huber L, Capen A, Chedid M, Ilaria R Jr, Smith MC, Stancato L.

Mol Cancer Ther. 2011 Nov;10(11):2168-78. doi: 10.1158/1535-7163.MCT-11-0323. Epub 2011 Sep 8.

19.

Mitotic spindle checkpoint inactivation by trichostatin a defines a mechanism for increasing cancer cell killing by microtubule-disrupting agents.

Dowling M, Voong KR, Kim M, Keutmann MK, Harris E, Kao GD.

Cancer Biol Ther. 2005 Feb;4(2):197-206. Epub 2005 Feb 8.

PMID:
15753652
20.

Bisubstrate inhibitor approach for targeting mitotic kinase Haspin.

Kestav K, Lavogina D, Raidaru G, Chaikuad A, Knapp S, Uri A.

Bioconjug Chem. 2015 Feb 18;26(2):225-34. doi: 10.1021/bc500464r. Epub 2015 Jan 29.

PMID:
25595038

Supplemental Content

Support Center